The company reached a definitive agreement to acquire Alliqua BioMedical (NAS:ALQA) through a reverse merger on October 12, 2018. Earlier, the company raised $16 million of Series B venture funding in a round led by TPG Biotech on January 9, 2017, putting the pre-money valuation at $30 million. Domain Associates also participated in this round.
Leave a Reply ·
You must be logged in to post a comment.